BusinessBeyondSpring Meets Primary Objective in Phase 2 Portion of Phase 2/3 Trial (Study 105) with Plinabulin for the Prevention of Docetaxel Chemotherapy-Induced Neutropenia (CIN)By Nasdaq OMXDec 14, 2017, 1:01 PM UTC
BusinessCascadian Therapeutics Added to the Nasdaq Biotechnology IndexBy Nasdaq OMXDec 13, 2017, 1:35 PM UTC
BusinessProlonged Progression-Free Survival Reinforces Tucatinib’s Potential for Patients with Advanced HER2+ Metastatic Breast CancerBy Nasdaq OMXDec 7, 2017, 9:05 PM UTC
BusinessBeyondSpring’s Lead Asset, Plinabulin, Recognized as 2017 National Science and Technology Major Project in ChinaBy Nasdaq OMXDec 4, 2017, 12:00 PM UTC
BusinessBeyondSpring Initiates Global Phase 2/3 Trial with Plinabulin in China for the Prevention of Chemotherapy-Induced Neutropenia to Demonstrate SuperiorityBy Nasdaq OMXNov 30, 2017, 2:58 PM UTC
BusinessPress Release PetVivo Adds Mr. David Merrill to the Board of DirectorsBy Nasdaq OMXNov 9, 2017, 4:29 PM UTC
BusinessCascadian Therapeutics Reports Third Quarter 2017 Financial ResultsBy Nasdaq OMXNov 8, 2017, 9:01 PM UTC
